The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes
Open accessAbstract
Aims To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality.Methods We identified a clinical cohort of male veterans in the United States who were ≥65years old with T2D and free from ARCs during 2002-2003. ARC diagnoses during 2004-2012 were analyzed using latent class modeling adjusted for confounders.Results The cohort consisted of 41,204 T2D men with age 74.6±5.8years, HbA1c 6.5±0.97%, and 8393 (20.4%) metformin users. Four ARC classes were identified. 'Healthy Class' (53.6%): metformin reduced likelihoods of all ARCs (from 0.14% in dementia to 6.1% in CVD). 'High Cancer Risk Class' (11.6%): metformin reduced likelihoods of CVD (13.3%), cancer (45.5%), depression (5.0%), and FRD (13.7%). 'High CVD Risk Class' (17.4%): metformin reduced likelihoods of CVD (48.6%), cancer (3.2%), depression (2.8%), and FRD (6.3%). 'High Frailty Risk Class' (17.2%): metformin reduced likelihoods of CVD (18.8%), cancer (3.9%), dementia (3.8%), depression (15.6%), and FRD (23.8%).Conclusions Metformin slowed ARC development in old men with T2D, and these effects varied by ARC phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In our case, the factors after 5 years of treatment are 0.52 for dementia, 0.33 for cardiovascular diseases, 0.32 for cancer, 0.29 for depression and 0.58 for frailty-related diseases.”
From The economic value of targeting aging (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on ref. 28, metformin has a sizable effect on LE. For the case in which treatment starts at age 75, LE at birth rises by 2.9 years, at 20 years rises by 3.0 years, at 40 years rises by 3.0 years, at 60 years rises by 3.3 years, and at 80 years rises by 4.3 years. The additions to remaining HLE vary from 1.7 to 2.5 years.”
From The economic value of targeting aging (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As ref. 28 only includes men over the age of 65 with diabetes, the factors may not accurately capture the impact of metformin on women, individuals who do not have diabetes, or those aged under 65.”
From The economic value of targeting aging (2021) · cites this paper as [28]
In the citing paper
“treatment with metformin reduced the risk of multiple age-related diseases, including CVDs, cancer, depression, and frailty-related diseases”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [254]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 1×
“…and mortality prevention requires further investigation (for example, empagliflozin has shown potential CVD prevention benefit in adults with T2D (Zinman et al., 2015)), this study provides important data for designing prospective studies aimed at examining the pleiotropic effects of metformin…”
BackgroundPrediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Prevalence, Expenditures, and Complications of Multiple Chronic Conditions in the Elderly
Wolff, J. L., Starfield, B. H., & Anderson, G. F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.20.2269 · Cited by 2,237
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Causes and consequences of comorbidity
Gijsen, R., Hoeymans, N., Schellevis, F. G., Ruwaard, D., Satariano, W. A., & van den Bos, G. A. M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00363-2 · Cited by 962
Felice, F. G. D., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 676
Hanley, A. J., Williams, K., D, M. P. S. M., & Haffner, S. M. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1177 · Cited by 637
Relationship Between Multimorbidity and Health-Related Quality of Life of Patients in Primary Care
Fortin, M., Bravo, G., Hudon, C., Lapointe, L., Almirall, J., Dubois, M., & Vanasse, A. (2006) · Quality of Life Research · doi:10.1007/s11136-005-8661-z · Cited by 615
Sahra, I. B., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P., MARCHAND‐BRUSTEL, Y. L., Giorgetti‐Peraldi, S., Cormont, M., Bertolotto, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2782 · Cited by 549
Wang, J., Gallagher, D., DeVito, L. M., Cancino, G. I., Tsui, D., He, L., Keller, G. M., Frankland, P. W., Kaplan, D. R., & Miller, F. D. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.016 · Cited by 474
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Insulin Resistance and Inflammation as Precursors of Frailty: The Cardiovascular Health Study
Barzilay, J. I. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.7.635 · Cited by 453
Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03916.x · Cited by 393
Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling
Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., Williamson, R., Fuchs, M., Köhler, A., Glossmann, H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912793107 · Cited by 380
Hsu, C.-C., Wahlqvist, M. L., Lee, M.-S., & Tsai, H.-N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101524 · Cited by 372
Lamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 369
Increased risk of cognitive impairment in patients with diabetes is associated with metformin
Moore, E. M., Mander, A. G., Ames, D., Kotowicz, M. A., Carne, R. P., Brodaty, H., Woodward, M., Boundy, K., Ellis, K. A., Bush, A. I., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0229 · Cited by 349
Bonora, E., Kiechl, S. J., Willeit, J., Oberhollenzer, F., Egger, G., Meigs, J. B., Bonadonna, R. C., & Muggeo, M. (2007) · Diabetes Care · doi:10.2337/dc06-0919 · Cited by 348
Weight Loss of Black, White, and Hispanic Men and Women in the Diabetes Prevention Program
West, D. S., Prewitt, T. E., Bursac, Z., & Felix, H. C. (2008) · Obesity · doi:10.1038/oby.2008.224 · Cited by 306
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302
Wright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276
Jablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., et al. (2010) · Diabetes · doi:10.2337/db10-0543 · Cited by 271
Boussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.-P., Kassai, B., Moreau, A., Gueyffier, F., & Cornu, C. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001204 · Cited by 266
Insulin resistance and cancer: The role of insulin and IGFs
Djiogue, S., Nwabo Kamdje, A. H., Vecchio, L., Kipanyula, M. J., Farahna, M., Aldebasi, Y., & Seke Etet, P. F. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0324 · Cited by 263
Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity
Stuart, M. J., & Baune, B. T. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.10.001 · Cited by 257
Guo, M., Mi, J., Jiang, Q., Xu, J., Tang, Y., Tian, G., & Wang, B. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12265 · Cited by 225
Rao, A. D., Kuhadiya, N. D., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Frailty Transitions in the San Antonio Longitudinal Study of Aging
Espinoza, S. E., Jung, I., & Hazuda, H. P. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03882.x · Cited by 207
Self-citationThakkar, B., Aronis, K. N., Vamvini, M. T., Shields, K. S., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.014 · Cited by 188
for the DIGAMI 2 Investigators, Mellbin, L., Malmberg, K., Norhammar, A., Wedel, H., & Rydén, L. (2011) · Diabetologia · doi:10.1007/s00125-011-2084-x · Cited by 107
The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk
Gremese, E., & Ferraccioli, G. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.04.018 · Cited by 105
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function
Chen, Y., Teranishi, K. S., Li, S., Yee, S. W., Hesselson, S., Stryke, D., Johns, S. J., Ferrin, T. E., Kwok, P., & Giacomini, K. M. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.19 · Cited by 102
Metformin: Intrinsic Vasculoprotective Properties
Wiernsperger, N. F. (2000) · Diabetes Technology & Therapeutics · doi:10.1089/15209150050025230 · Cited by 75
Wang, C., Lorenzo, C., & Espinoza, S. E. (2014) · PubMed · Cited by 62
Self-citationLehman, D. M., Lorenzo, C., Hernández, J., & Wang, C.-P. (2012) · Diabetes Care · doi:10.2337/dc11-1829 · Cited by 58
Self-citationKowall, B., Rathmann, W., & Kostev, K. (2014) · Diabetes Care · doi:10.2337/dc14-0977 · Cited by 49
Pugh, J. A., Wang, C., Espinoza, S. E., Noël, P. H., Bollinger, M., Amuan, M. E., Finley, E. P., & Pugh, M. J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12656 · Cited by 43
Self-citationHyperinsulinemia and type 2 diabetes: Impact on cancer
Novosyadlyy, R., & LeRoith, D. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11512 · Cited by 40
Impact of metformin on metastases in patients with breast cancer and type 2 diabetes
Jacob, L., Kostev, K., Rathmann, W., & Kalder, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.003 · Cited by 34
Holden, S. E., Jenkins‐Jones, S., & Currie, C. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153594 · Cited by 31
Metformin Use and Cognitive Dysfunction Among Patients with Diabetes Mellitus
Liccini, A. P., Malmstrom, T. K., & Morley, J. E. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.08.026 · Cited by 22
Wang, C., Jo, B., & Brown, C. H. (2014) · Statistics in Medicine · doi:10.1002/sim.6120 · Cited by 13
Self-citationDiabetes Research in the Department of Veterans Affairs
Reiber, G. E., & Boyko, E. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.suppl_2.b95 · Cited by 12
Cited by
Sorted by citations
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 316
Metadata
- Authors
- Wang, C.-P., Lorenzo, C., Habib, S. L., Jo, B., & Espinoza, S. E.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Stanford Medicine (US)
- Corresponding author
- Wang, Chen-Pin
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 31
- Issue
- 4
- Pages
- 679-686
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- PMC
- PMC5654524
- OpenAlex
- W2582066920
- Cited by
- 134
- References
- 50
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 10 · 2023: 16 · 2022: 23 · 2021: 16 · 2020: 18 · 2019: 14 · 2018: 12 · 2017: 3
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Diabetes and its Complications (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R21CA161180)
- National Institute on Aging (P30AG04427)
- National Institute on Drug Abuse (R01DA31698)
- South Texas Veterans Health Care System, San Antonio, Texas
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Keywords
- metformin, type 2 diabetes, older men, age-related comorbidities, cardiovascular disease, cancer, depression, dementia, frailty, mortality, veterans, treatment effect heterogeneity, latent class analysis
- MeSH terms
- Aged, Aged, 80 and over, Aging, Cardiovascular Diseases, Dementia, Depression, Diabetes Mellitus, Type 2, Drug Resistance, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Metformin, Mortality, Neoplasms, Risk, United States, United States Department of Veterans Affairs, Cohort Studies, Comorbidity, Prevalence, Frail Elderly, Electronic Health Records, Veterans Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
